Senior Business Consultant

Platform built in collaboration with Amazon Web Services, Modus Create to produce unmatched accuracy, efficiencies and compliance for life science companiesCHICAGO – 10 April, 2025 - EVERSANA, a leading provider of commercial services to the life sciences industry, today announced the next milestone in its journey to transform and innovate commercialization with the launch of EVERSANA ORCHESTRATE MLR, an AI-powered, industry-integrated platform that revolutionizes the Medical, Legal, and Regulatory (MLR) process.EVERSANA ORCHESTRATE MLR automates 90 percent of common tasks in the complex review process through a single platform that’s easy to implement and complies with all regulatory requirements.The solution was built on Amazon Bedrock, which offers a choice of high-performing foundation models. EVERSANA worked with consulting firm Modus Create , EVERSANA’s Medical Affairs and Regulatory Affairs experts, and Veeva for seamless integration with Veeva PromoMats.“EVERSANA ORCHESTRATE MLR is a game-changer for the life science industry,” said Jim Lang, CEO. “Through the power of AI and our collaborations with leading technology providers and in-house MLR experts, we’ve set a new standard for efficiency, compliance, and quality that is much needed in today’s industry.”Shifting the Industry MLR Process from Manual to AutomatedMost organizations have a manual MLR review process, requiring teams to comb through hundreds of marketing materials and cross-reference them with the most accurate regulatory claims information available. EVERSANA ORCHESTRATE MLR automatically identifies, extracts and manages claims in minutes with the power of AI.Additionally, annotation and cross-referencing for creative-type documents against claims data can now be completed in just a few clicks. Users will see all claims identified in the document and what needs to be updated and can make these updates in real-time, resulting in 90 percent faster content updates and an overall reduction in content reviews by as much as 50 percent.By harnessing the power of Amazon Bedrock, EVERSANA will empower life sciences companies with the AI tools they need to mitigate a significant pain point for the healthcare industry— administrative burden. EVERSANA ORCHESTRATE MLR is just one example of how EVERSANA is using industry-leading AI solutions to solve some of healthcare’s most complex problems.“Generative AI is transforming the life sciences industry by accelerating R&D, improving efficiency in manufacturing, and streamlining the path to commercialization," said Dan Sheeran, general manager, Healthcare and Life Sciences, AWS

Cloud CTMS software to improve research site efficiency and integrate seamlessly with sponsorsPLEASANTON, Calif., April 1, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva SiteVault CTMS, a clinical trial management system for research sites that is integrated with SiteVault eISF and SiteVault eConsent to allow sites to comprehensively manage clinical trials within one main system. Integration with sponsors using Veeva's Clinical Platform gives sites seamless bidirectional data flow to sponsors to reduce manual processes and increase efficiency."We need to work efficiently to help more families enroll their children in studies and get lifesaving treatment," said Theresa Oswald, director of research operations and conduct at Ann & Robert H. Lurie Children's Hospital of Chicago. "In our experience, we have found that systems like Veeva SiteVault with a CTMS provide a streamlined user experience. This can help drive speed for the benefit of our patients.""We are excited to bring Veeva SiteVault CTMS to the industry," said Nick Frenzer, general manager, site solutions at Veeva. "High-quality cloud software and seamless sponsor integration will help sites be more efficient

Specialized CRO standardizes on Veeva RTSM to drive operational efficiency and faster study timelinesBARCELONA, Spain, March 19, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM study on Veeva RTSM. By standardizing with Veeva RTSM, Indero has strengthened its clinical trial operations, harnessing advanced RTSM capabilities and expert support to drive efficiency, enhance process consistency, and streamline execution."As we continue to optimize our clinical trial operations, Veeva RTSM has driven more efficient processes and closer collaboration to ensure seamless execution," said Eric Hardy, senior director, biometrics at Indero. "Because of this added speed and effectiveness, we can help bring therapies to market faster, allowing our sponsors, sites, and patients to benefit sooner."The launch of Indero's 40th RTSM study highlights the continued collaboration between the two organizations. Since first adopting Veeva RTSM, Indero has worked closely with Veeva to continuously refine and implement standardized processes that drive long-term success for its clinical trials."With its enterprise standard RTSM approach, Indero is achieving greater long-term efficiency and reliability in their studies," said Steve Simmerman, general manager, Veeva RTSM. "Partnering with Indero to standardize clinical processes will further accelerate study timelines, demonstrating a streamlined approach that can advance the industry."Additional InformationTo learn more about Veeva's enterprise standard RTSM, visit www.veeva.com/rtsm.About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs